Announcing Positive Results of Saturn-2 Phase 3 Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis
Revolutionizing treatment for patients in need
Scroll To Discover
About
We’re committed to delivering boundless therapeutic ingenuity
Tarsus Pharmaceuticals, Inc. is a biopharmaceutical company that embodies the values of commitment, empowerment, and teamwork. We aim to bring novel therapeutics to patients across a range of diseases with limited treatment options.
Pipeline
Novel therapies, beginning with the eye
For the millions of patients living with Demodex blepharitis, an FDA-approved treatment is on the horizon.
News & Media
Here is the latest from Tarsus
09/27/2022
Tarsus to Present Saturn-2 Pivotal Phase 3 Trial Data and Saturn-1 Extension Study Long-Term Safety Data Evaluating TP-03 for the Treatment of Demodex Blepharitis at Upcoming Eye Care Meetings
09/07/2022
Tarsus Submits New Drug Application to the FDA for TP-03 for the Treatment of Demodex Blepharitis
08/11/2022
Tarsus Reports Second Quarter 2022 Financial Results and Recent Business Achievements
15440 Laguna Canyon Road, Ste 160
Irvine, CA 92618
2022 Tarsus Pharmaceuticals, Inc. All rights reserved.
TARSUS and the associated logo are trademarks of Tarsus Pharmaceuticals, Inc.
Contact Tarsus
Please reach out to us using the form below."*" indicates required fields